Evaluating Tolerability of ePUHRT With Brachytherapy Boost

Launched by INDIANA UNIVERSITY · Feb 5, 2025

Keywords

ClinConnect Summary

This clinical trial is studying a new way to treat prostate cancer by combining two types of radiation therapy: Elective Pelvic Ultra Hypofractionated Irradiation Treatment (ePUHRT), which is a type of external radiation, and High Dose Rate Brachytherapy Boost, an internal radiation method. The goal is to see how well patients tolerate this combined treatment and to monitor any side effects that may occur.

To participate in this trial, you must be at least 18 years old and have been diagnosed with a specific type of prostate cancer that is considered intermediate to high risk. You should also be in good health overall, as measured by a performance score, and planning to undergo the standard brachytherapy procedure. However, if you have had previous radiation therapy to the pelvic area, certain surgeries, or other specific health conditions, you may not be eligible. If you join the trial, you can expect close monitoring during your treatment to ensure your safety and comfort. This study is currently looking for participants, so it's a great opportunity to help advance prostate cancer treatment.

Gender

MALE

Eligibility criteria

• Inclusion Criteria:
• • 1. ≥ 18 years old at the time of informed consent
• • 2. Capable of providing informed consent and HIPAA authorization
• • 3. Karnofsky performance score ≥ 70
• • 4. Pathologically confirmed unfavorable intermediate, high, and very high-risk prostate cancer per treating physician
• • 5. Candidate plans to undergo the standard of care prostate high dose brachytherapy boost procedure
• • 6. Up to date colon cancer screen per per American Cancer Society guidelines
• Exclusion Criteria:
• • 1. Prior pelvic irradiation treatment
• • 2. Prior rectal surgery which precludes instrumentation with rectal ultrasound probe.
• • 3. Evidence of nodal or distant disease on screening diagnostic work up.
• • 4. Prior prostatectomy, Holmium laser enucleation of the prostate or transurethral resection of the prostate procedure
• • 5. International Prostate Symptom Score (IPSS) score \> 16 despite medical therapy